Katharina Fleischhauer

Katharina Fleischhauer

Auto-generated profile, based on publicly available information

Katharina Fleischhauer

Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
PCPietro Crivello
Pietro Crivello
LZLaura Zito
Laura Zito
FSFederico Sizzano
Federico Sizzano
EZElisabetta Zino
Elisabetta Zino
Martin MaiersMartin Maiers
Martin Maiers
KFKatharina Fleischhauer
Katharina Fleischhauer
A major challenge in unrelated hematopoietic stem cell transplantation (HSCT) is the prediction of permissive HLA mismatches, ie, those associated with lower clinical risks compared to their nonpermissive counterparts. For HLA-DPB1, a clinically prognostic model has been shown to be matching for T cell epitope (TCE) groups assigned by cross reactivity of T cells alloreactive to HLA-DPB1∗09:01; however, the molecular basis of this observation is not fully understood. Here, we have mutated amino acids (aa) in 10 positions of HLA-DPB1∗09:01 to other naturally occurring variants, expressed them by lentiviral vectors in B cell lines, and quantitatively measured allorecognition by 17 CD4(+) T cell effectors from 6 unrelated individuals. A significant impact on the median alloresponse was observed for peptide contact positions 9, 11, 35, 55, 69, 76, and 84, but not for positions 8, 56, and 57 pointing away from the groove. A score for the "functional distance" (FD) from HLA-DPB1∗09:01 was defined as the sum of the median impact of polymorphic aa in a given HLA-DPB1 allele on T cell alloreactivity. Established TCE group assignment of 23 alleles correlated with FD scores of ≤0.5, 0.6 to 1.9 and ≥2 for TCE groups 1, 2, and 3, respectively. Based on this, prediction of TCE group assignment will be possible for any given HLA-DPB1 allele, including currently 367 alleles encoding distinct proteins for which T cell cross reactivity patterns are unknown. Experimental confirmation of the in silico TCE group classification was successfully performed for 7 of 7 of these alleles. Our findings have practical implications for the applicability of TCE group matching in unrelated HSCT and provide new insights into the molecular mechanisms underlying this model. The innovative concept of FD opens new potential avenues for risk prediction in unrelated HSCT.

31 August 2017 in Blood
Verified
Journal Article
Open access
PDF file
KFKatharina Fleischhauer
Katharina Fleischhauer
BSBronwen E. Shaw
Bronwen E. Shaw
When considering HLA-matched hematopoietic cell transplantation (HCT), sibling and unrelated donors (UDs) are biologically different because UD-HCT is typically performed across HLA-DP disparities absent in sibling HCT. Mismatched HLA-DP is targeted by direct alloreactive T cell responses with important implications for graft-versus-host disease and graft-versus-leukemia. This concise review details special features of HLA-DP as model antigens for clinically permissive mismatches mediating limited T-cell alloreactivity with minimal toxicity, and describes future avenues for their exploitation in cellular immunotherapy of malignant blood disorders.

18 February 2021 in Blood
Verified
Journal Article
Closed access
PDF file
TMThuja Meurer
Thuja Meurer
PCPietro Crivello
Pietro Crivello
MMMaximilian Frederik Metzing
Maximilian Frederik Metzing
MKMichel Kester
Michel Kester
DMDominik Andre Megger
Dominik Andre Megger
KFKatharina Fleischhauer
Katharina Fleischhauer
In hematopoietic cell transplantation (HCT), permissive HLA-DPB1 mismatches between patients and their unrelated donors (UD) are associated with improved outcomes compared to non-permissive mismatches, but the underlying mechanism is incompletely understood. Here we used mass spectrometry, T-cell receptor-beta (TCRb) deep sequencing, and cellular in vitro models of alloreactivity to interrogate the HLA-DP immunopeptidome and its role in alloreactive T cell responses. We find that permissive HLA-DPB1 mismatches display significantly higher peptide repertoire overlaps compared to their non-permissive counterparts, resulting in lower frequency and diversity of alloreactive TCRb clonotypes in healthy individuals and transplanted patients. Permissiveness can be reversed by the absence of the peptide editor HLA-DM, or the presence of its antagonist HLA-DO, through significant broadening of the peptide repertoire. Our data establish the degree of immunopeptidome divergence between donor and recipient as the mechanistic basis for the clinically relevant permissive HLA-DPB1 mismatches in HCT, and show that permissiveness is dependent on HLA-DM-mediated peptide editing. Its key role for harnessing T-cell alloreactivity to HLA-DP highlights HLA-DM as a potential novel target for cellular and immunotherapy of leukemia.

1 April 2016 in Seminars in Hematology
Verified
Journal Article
Closed access
PDF file
KFKatharina Fleischhauer
Katharina Fleischhauer
DBDietrich W. Beelen
Dietrich W. Beelen

7 July 2016 in Blood
Verified
Journal Article
Closed access
PDF file
PCPietro Crivello
Pietro Crivello
AHAndreas Heinold
Andreas Heinold
VRVera Rebmann
Vera Rebmann
HOHellmut D. Ottinger
Hellmut D. Ottinger
PHPeter A. Horn
Peter A. Horn
KFKatharina Fleischhauer
Katharina Fleischhauer
Key Points: Nonpermissive mismatches associated with survival after HCT reflect FD between recipient-donor HLA-DPB1. FD within HLA-DPB1 is determined by the combined impact of nonconservative peptide-binding AA substitutions.

16 April 2020 in Blood
Verified
Journal Article
Open access
PDF file
JSJohannes Schetelig
Johannes Schetelig
HBHenning Baldauf
Henning Baldauf
FHFalk Heidenreich
Falk Heidenreich
CMCarolin Massalski
Carolin Massalski
SFSandra Frank
Sandra Frank
MBMartin Bornhäuser
Martin Bornhäuser
Several studies suggest that harnessing natural killer (NK) cell reactivity mediated through killer cell immunoglobulin-like receptors (KIRs) could reduce the risk of relapse after allogeneic hematopoietic cell transplantation. Based on one promising model, information on KIR2DS1 and KIR3DL1 and their cognate ligands can be used to classify donors as KIR-advantageous or KIR-disadvantageous. This study was aimed at externally validating this model in unrelated donor hematopoietic cell transplantation. The impact of the predictor on overall survival (OS) and relapse incidence was tested in a Cox regression model adjusted for patient age, a modified disease risk index, Karnofsky performance status, donor age, HLA match, sex match, cytomegalovirus match, conditioning intensity, type of T-cell depletion, and graft type. Data from 2222 patients with acute myeloid leukemia or myelodysplastic syndrome were analyzed. KIR genes were typed by using high-resolution amplicon-based next-generation sequencing. In univariable analyses and subgroup analyses, OS and the cumulative incidence of relapse of patients with a KIR-advantageous donor were comparable to patients with a KIR-disadvantageous donor. The adjusted hazard ratio from the multivariable Cox regression model was 0.99 (Wald test, P = .93) for OS and 1.04 (Wald test, P = .78) for relapse incidence. We also tested the impact of activating donor KIR2DS1 and inhibition by KIR3DL1 separately but found no significant impact on OS and the risk of relapse. Thus, our study shows that the proposed model does not universally predict NK-mediated disease control. Deeper knowledge of NK-mediated alloreactivity is necessary to predict its contribution to graft-versus-leukemia reactions and to eventually use KIR genotype information for donor selection.